Pharvaris ($PHVS) Stock Hub: CHAPTER-3 meets its primary and all secondary efficacy endpoints

01 Why $PHVS is a two-catalyst file, not one

Pharvaris now has positive pivotal results for both HAE tracks: RAPIDe-3 for IR on-demand and CHAPTER-3 for once-daily XR prophylaxis. The IR NDA has an April 23, 2027 PDUFA; XR submissions are planned from H1 2027. They remain separate regulatory programs.

The positive CHAPTER-3 result supports the dual-use development strategy. Its commercial value still depends on the full efficacy and safety profile, regulatory approval, reimbursement and adoption in a competitive HAE market.

02 CHAPTER-3 positive results published September 8

Pharvaris now has positive pivotal results for both HAE tracks: RAPIDe-3 for IR on-demand and CHAPTER-3 for once-daily XR prophylaxis. The IR NDA has an April 23, 2027 PDUFA; XR submissions are planned from H1 2027. They remain separate regulatory programs.

The August 12 company update reports 85 randomized participants, 2:1, on 40 mg XR daily or placebo for 24 weeks. The registry still carries an older estimate of 81. We use the newer company count and retain the discrepancy explicitly. FDA review of the separate IR capsule has an April 23, 2027 PDUFA date; neither NDA acceptance nor supportive congress analyses establish approval.

IR · Q2 · CHAPTER-3 registry

03 September evidence and the event calendar

The September 3 release covers regional RAPIDe-3 analyses, CHAPTER-1 extension results, cardiovascular assessments and modeling of combined IR/XR exposure. These are supportive analyses from existing programs. Nonclinical modeling is not clinical proof of the combined regimen, and no observed cardiovascular signal in the analyzed dataset cannot exclude rare or future risk.

IR · September 3

Conference attendance is not a promise to release CHAPTER-3 data. The September 3–4 Bradykinin Symposium is now a past event.

IR · Current events

04 Pharvaris Investor Snapshot

Pharvaris is a late-stage biotechnology company focused on bradykinin-mediated angioedema. Its entire current investment case is centered on deucrictibant, an orally bioavailable small-molecule antagonist of the bradykinin B2 receptor. The molecule is being developed in two formulations: an immediate-release capsule for treating attacks after they begin and an extended-release tablet for preventing attacks through once-daily prophylaxis.

The distinction matters because the company is not trying to build two unrelated products. It is attempting to establish a single active ingredient across both major treatment paradigms. If successful, a patient could potentially use deucrictibant XR for prevention and deucrictibant IR for breakthrough attacks. Pharvaris argues that this continuity could simplify patient experience and create a differentiated franchise. It stays a strategic hypothesis until approvals, labels, reimbursement and real-world use confirm it.

Why the setup is attractive

• RAPIDe-3 met its primary and all 11 secondary efficacy endpoints with statistical significance.
• The FDA accepted the deucrictibant IR NDA and assigned a specific action date.
• CHAPTER-3 offers a separate near-term value inflection in prophylaxis.
• The mechanism is clinically validated by injectable icatibant.
• Cash runway extends beyond the major visible milestones.

Why the setup is not low risk

• CHAPTER-3 contains only 85 participants reported by the company and must reproduce an unusually strong Phase 2 signal.
• The oral on-demand market is no longer empty because EKTERLY launched in 2025.
• The prophylaxis market became more competitive with DAWNZERA and ANDEMBRY approvals.
• FDA acceptance confirms review, not approvability.
• The company remains pre-revenue and dependent on capital markets until commercialization succeeds.

05 Company Profile, Corporate Structure and History

Pharvaris N.V. was incorporated in 2015 and is organized under Dutch law. Pharvaris is a Dutch company headquartered in Zug, Switzerland, with offices in Leiden, the Netherlands, and Lexington, Massachusetts. Its ordinary shares trade on the Nasdaq Global Select Market under the ticker PHVS. Pharvaris is a foreign private issuer and reports under International Financial Reporting Standards, with the euro as its reporting currency.

The scientific heritage is relevant. Members of the founding team were involved in the discovery and development of icatibant, the injected bradykinin B2 receptor antagonist that validated the target in acute HAE treatment. Pharvaris is attempting to retain the downstream B2-receptor mechanism while replacing the injection with an oral small molecule that can be formulated for either rapid or sustained exposure.

The company completed its initial public offering in 2021. Since then, its development path has included a major regulatory interruption: U.S. clinical studies were placed on hold in August 2022 after nonclinical toxicology findings in animals. The FDA lifted the holds in two separate stages: the on-demand IND in June 2023, after an interim analysis of a long-term rodent study, and the prophylaxis IND in January 2024, once the complete data set was available. That history should not be erased from the narrative. It demonstrates that the company has already experienced a material regulatory setback, completed additional work and returned both formulations to late-stage development. It also explains why long-term safety and regulatory interpretation stay on the file.

06 Hereditary Angioedema: Disease Burden and Market Context

Hereditary angioedema is a rare disorder characterized by recurrent, unpredictable episodes of swelling. Attacks can affect the extremities, face, abdomen, genitals and upper airway. Abdominal attacks can cause severe pain, nausea and vomiting. Laryngeal swelling can be life-threatening because it may obstruct the airway. Unlike histamine-mediated allergic swelling, classic HAE attacks are driven by excess bradykinin and generally do not respond to antihistamines, corticosteroids or epinephrine in the same way as ordinary allergic reactions.

HAE type I is usually associated with deficient levels of functional C1 inhibitor, while type II involves dysfunctional C1 inhibitor. A smaller and heterogeneous group has HAE with normal C1 inhibitor. The unpredictable timing of attacks creates a burden that extends beyond attack frequency: patients may delay travel, work, school or social activity because they cannot know where or when swelling will begin.

Treatment divides into two broad categories. On-demand treatment is taken when an attack begins, ideally as early as possible. Long-term prophylaxis is taken regularly to reduce attack frequency. Patients receiving prophylaxis still require access to rescue treatment because breakthrough attacks can occur. This dual requirement is the foundation of Pharvaris’ franchise strategy.

The market is attractive but no longer underdeveloped

HAE is a rare disease, yet it supports multiple high-value products because treatment is chronic, specialized and clinically necessary. Pharvaris’ presentation cites an internally sourced prediction of a U.S. HAE market reaching approximately $4.7 billion in 2036. That figure should be understood as a company-presented market estimate rather than an independently guaranteed outcome.

Competition has accelerated. The United States now has several effective prophylactic options, including injectable Takhzyro, oral Orladeyo, monthly ANDEMBRY and DAWNZERA, which can be dosed every four or eight weeks. The acute-treatment landscape includes C1 inhibitor products, injectable icatibant and oral EKTERLY. Deucrictibant therefore does not need merely to work; it needs a profile strong enough to win use in a market where patients and physicians already have credible choices.

07 Deucrictibant Science: Why the Bradykinin B2 Receptor Matters

Bradykinin increases vascular permeability by binding to the bradykinin B2 receptor. In HAE, excessive bradykinin signaling allows fluid to leave blood vessels and enter surrounding tissue, producing swelling. The contact-system pathway that generates bradykinin includes factor XII, plasma kallikrein and high-molecular-weight kininogen. Several competing products intervene upstream by inhibiting kallikrein, factor XIIa or prekallikrein production.

Deucrictibant acts downstream by blocking the B2 receptor itself. This approach is clinically validated by icatibant, which is approved for acute HAE attacks and is administered by subcutaneous injection. Pharvaris’ central scientific proposition is that a potent oral B2-receptor antagonist can deliver the target-level benefit of icatibant without injection burden.

The downstream mechanism may also be relevant beyond classic HAE types I and II. Because the receptor sits at the final signaling step, Pharvaris argues that it may work across bradykinin-mediated forms of angioedema regardless of which upstream pathway produces excess bradykinin. This is the rationale for including HAE with normal C1 inhibitor in RAPIDe-3 and for developing deucrictibant in acquired angioedema due to C1 inhibitor deficiency.

Immediate-release capsule

The 20 mg IR capsule is designed to reach therapeutic exposure rapidly. In RAPIDe-3, the median time to End of Progression was approximately 17.5 minutes and the median time to onset of symptom relief was 1.28 hours. The intended commercial use is treatment at the earliest recognition of an attack.

Extended-release tablet

The 40 mg XR tablet is designed to maintain therapeutic exposure over 24 hours and support once-daily prophylaxis. CHAPTER-3 uses the intended commercial formulation, making the pivotal readout directly relevant to the product Pharvaris plans to market.

Mechanism strength does not guarantee formulation success

Target validation and product validation are two different things here. The B2 receptor is validated. Oral deucrictibant’s clinical profile still depends on absorption, exposure, duration, adherence, drug interactions, safety and manufacturing consistency. A valid mechanism can still produce a commercially mediocre product if the formulation does not achieve competitive exposure or if tolerability limits chronic use.

08 Pharvaris Pipeline Map

The pipeline appears broad because it contains four named programs, but all are based on the same active ingredient and mechanism. This creates operating leverage if deucrictibant succeeds: manufacturing knowledge, safety data, physician education and brand investment can support multiple uses. The same structure magnifies downside if an unexpected molecule-level safety issue emerges.

09 RAPIDe-3: The Positive Phase 3 Foundation

RAPIDe-3 was a global, randomized, double-blind, placebo-controlled crossover study evaluating deucrictibant IR for on-demand treatment of HAE attacks in patients aged 12 to 75. The study enrolled 134 participants from 24 countries on six continents. Eighty-eight participants generated the paired efficacy comparison in which one qualifying attack was treated with deucrictibant and another with placebo.

The crossover design is useful in a heterogeneous disease because each participant can contribute data under both treatment conditions. Attack location and severity can still differ, so the design does not eliminate all variability, but it reduces some between-patient noise.

Headline efficacy results

Pharvaris reported that RAPIDe-3 met the primary endpoint and all 11 secondary efficacy endpoints with statistical significance. The company also reported no treatment-related serious adverse events and no discontinuations due to treatment-emergent adverse events. These are strong results, but the current evidence remains largely company-sponsored and conference-presented. Regulatory review will test the full dataset, including missing data, attack adjudication, population heterogeneity, repeat dosing, exposure and manufacturing.

End of Progression: useful endpoint or marketing construction?

End of Progression is defined as the earliest timepoint after treatment after which all subsequent symptom-change ratings remain stable or improved through the specified assessment window. Clinically, the concept is intuitive: patients want to know when an attack has stopped getting worse. The very rapid 17.47-minute median is potentially meaningful because delayed treatment can allow attacks to become more severe.

However, End of Progression is a Pharvaris-defined and trademarked term. The FDA will decide how much weight it receives in labeling and promotional claims. The accepted endpoints are symptom relief, severity reduction, complete resolution and rescue-medication use. A fast EoP result supports differentiation, but it should not substitute for the broader efficacy package.

10 FDA Pathway and the April 23, 2027 PDUFA Date

On July 6, 2026, Pharvaris announced that the FDA accepted the New Drug Application for deucrictibant IR 20 mg capsules for on-demand treatment of HAE attacks in patients aged 12 and older. The agency assigned a PDUFA action date of April 23, 2027.

NDA acceptance means the FDA determined that the application was sufficiently complete for substantive review. It does not mean the agency has concluded that the drug is safe, effective, manufacturable or approvable. The review can still produce information requests, labeling negotiations, inspection issues, a delayed action date or a Complete Response Letter.

Factors supporting the filing

• Positive placebo-controlled pivotal Phase 3 data.
• A paired efficacy analysis in 88 participants, drawn from 24 countries and six continents.
• A validated therapeutic mechanism.
• Statistical significance across all prespecified major efficacy endpoints.
• A reported well-tolerated profile without treatment-related serious adverse events in RAPIDe-3.

Factors that remain under FDA review

• Completeness and consistency of the safety database.
• Use in HAE with normal C1 inhibitor and the final scope of the label.
• Dosing, repeat dosing and interaction with prophylactic therapies.
• Commercial manufacturing, validation and facility readiness.
• Post-marketing commitments and pediatric requirements.

The company has orphan drug designation in the United States, European Union and Switzerland. Orphan designation can provide development incentives and, if the statutory requirements are met, market exclusivity after approval. It does not prevent competition from drugs with different active ingredients or mechanisms, and it does not guarantee that deucrictibant will receive approval.

11 CHAPTER-3: Results and the Evidence to Assess

CHAPTER-3 randomized 85 participants, 55 to deucrictibant XR 40 mg once daily and 30 to placebo for 24 weeks. The September 8 results met the primary endpoint with an 83% reduction in mean monthly attacks versus placebo (p<0.0001), and all secondary efficacy endpoints. No treatment-related serious adverse events were reported.

The primary question is the rate of investigator-confirmed HAE attacks during the treatment period. Additional measures include treatment-emergent adverse events, pharmacokinetics, attack severity, use of on-demand medication and health-related quality of life.

Criteria for assessing the reported results

• Clear statistical significance on the primary monthly attack-rate endpoint.
• A low absolute attack rate, not merely a favorable percentage reduction against a high placebo rate.
• Competitive attack-free rates over the six-month treatment period.
• Reductions in moderate or severe attacks and in attacks requiring rescue medication.
• Consistent benefit across relevant subgroups, including baseline attack frequency, age and geographic region.
• Clean chronic-use tolerability, with low discontinuation and no concerning cardiovascular, hepatic or laboratory pattern.
• Evidence that protection begins rapidly, supporting the company’s claim that steady state is achieved within two to three days.

Why a statistically positive readout could still disappoint

The market will compare deucrictibant with highly effective injectables and newer long-interval therapies. A positive trial with a modest absolute benefit could be commercially weak. Investors are likely to focus on whether once-daily oral convenience is paired with efficacy close enough to Takhzyro, DAWNZERA or ANDEMBRY to drive switching. If efficacy resembles the more modest profile historically associated with oral Orladeyo, the commercial differentiation may narrow.

Sample size is another sensitivity. Eighty-five participants is reasonable for a rare-disease pivotal study, but subgroup analyses may be small and unstable. One or two participants with unusually high attack rates can influence the aggregate result. The full distribution, confidence intervals and treatment exposure will matter more than a single percentage headline.

Registry check September 6: NCT06669754 is ACTIVE_NOT_RECRUITING, with the last record posted February 13. Estimated August 2026 primary and study completion dates are planning fields, not confirmation of database lock or a readout. Its estimated 81-person enrollment predates the August company statement of 85 actually randomized.

12 CHAPTER-1: The Phase 2 Evidence Behind the Pivotal Bet

CHAPTER-1 was a randomized, placebo-controlled Phase 2 study in 34 adults with HAE type I or II. Participants received placebo, deucrictibant 20 mg per day or 40 mg per day for 12 weeks. The study used the immediate-release formulation dosed twice daily during the randomized phase, while CHAPTER-3 evaluates the intended once-daily extended-release commercial formulation.

At the 40 mg daily dose, Pharvaris reported an 84.5% reduction in mean monthly HAE attack rate versus placebo. The company also reported a 92.3% reduction in moderate or severe attacks and a 92.6% reduction in attacks requiring on-demand treatment versus placebo. The company reported no serious adverse events, no severe treatment-emergent adverse events and no adverse events leading to discontinuation. Severe attacks were absent in the placebo arm as well, so the absence of severe attacks on deucrictibant should not be read as a treatment effect: the quantified comparison is the 92.3% reduction in moderate or severe attacks.

Participants completing the randomized phase could enter a long-term open-label extension. Final extension data presented in 2026 showed an average reduction in attack frequency of approximately 92% from baseline, with about half of participants remaining attack-free throughout the extension. Treatment exposure extended to approximately 34 months for some participants before transition into CHAPTER-4.

What CHAPTER-1 established

• Strong proof of concept for B2-receptor blockade as prophylaxis.
• Durability over a multi-year extension.
• Low attack rates and reduced rescue-medication use.
• No reported treatment-related serious adverse events or discontinuations in the final extension summary.

What CHAPTER-1 did not establish

• Definitive Phase 3 efficacy in a larger population.
• Performance of the final once-daily XR commercial formulation in a pivotal trial.
• Head-to-head superiority versus approved prophylactic therapies.
• Long-term real-world adherence and reimbursement.

Open-label extensions are useful for durability and safety but are vulnerable to selection bias. Patients who benefit and tolerate therapy are more likely to remain enrolled. Attack rates can also change over time. Therefore, the extension strengthens the case but cannot replace the blinded, placebo-controlled CHAPTER-3 result.

13 CHAPTER-4, CREAATE and the Broader Portfolio

CHAPTER-4 long-term extension

CHAPTER-4 is an open-label extension evaluating long-term once-daily deucrictibant XR. It enrols participants rolling over from CHAPTER-3 and earlier deucrictibant studies, and it can also enrol patients who have never received deucrictibant, so it is not a closed extension cohort. The data can support chronic-use safety, durability and patient-reported outcomes. Because prophylaxis may continue for years, the size and quality of the long-term exposure database will matter to regulators, physicians and payers.

CREAATE in acquired angioedema

CREAATE is a global pivotal Phase 3 study in acquired angioedema due to C1 inhibitor deficiency. Unlike hereditary disease, AAE-C1INH is acquired and can be associated with underlying lymphoproliferative or autoimmune conditions. The study includes prophylactic and on-demand components using the XR and IR formulations.

The commercial population is smaller than HAE, but the indication is underserved and mechanism-based. A successful program could expand the label and reinforce the idea that directly blocking the B2 receptor works across different sources of excess bradykinin. CREAATE sits further out than CHAPTER-3 or the accepted NDA, because enrollment and data timing are less immediate.

Beyond angioedema

Pharvaris and its scientific collaborators have discussed broader diseases in which bradykinin signaling may play a role, including chronic cough, asthma, allergic rhinitis and urticaria. These concepts are early and should be treated as optionality rather than current valuation pillars. Expanding into common inflammatory diseases would require substantial development, different trial designs and considerably more capital.

14 Commercial Opportunity: One Molecule, Two Treatment Settings

The most attractive version of the Pharvaris thesis is not simply “an oral attack drug” or “an oral prophylaxis tablet.” It is an integrated franchise in which one molecule can accompany patients across their disease journey. A patient with infrequent attacks might begin with deucrictibant IR on demand. If attack burden increases, the patient could move to daily XR prophylaxis while retaining IR for breakthrough attacks.

This could create familiarity and confidence in a single active ingredient. Physicians would already understand the mechanism and safety profile. Pharvaris could use a unified rare-disease commercial organization rather than building separate teams for unrelated assets. Manufacturing and medical affairs could also benefit from shared knowledge.

The commercial thesis depends on four separate wins

1. Regulatory approval: the IR capsule must clear FDA review, and XR must eventually produce a sufficient filing package.
2. Competitive labeling: the final indications, age ranges, dosing instructions and safety language must support use.
3. Payer access: oral convenience will not drive adoption if reimbursement requires failure of cheaper or established therapies.
4. Real-world behavior: patients must carry, take and trust the product early in attacks; prophylaxis patients must remain adherent to daily dosing.

Commercial preparation is already underway. The May 2026 financing was explicitly intended in part to fund expansion of the U.S. sales and marketing organization and launch preparation. This reduces execution risk compared with waiting until approval, but it also increases operating expenses before revenue is certain.

15 Competitive Landscape: The Bar Deucrictibant Faces

The HAE market now contains strong therapies across multiple mechanisms and dosing schedules. A clean comparison requires separating on-demand treatment from prophylaxis.

On-demand competitors

EKTERLY changes the investment debate. It was approved in July 2025 and generated approximately $49.1 million of global net product revenue in the eight-month transition period ended December 31, 2025, reported in KalVista’s transition report filed on March 25, 2026. Because the drug launched on July 7, 2025, that figure covers roughly six months of actual selling rather than eight. It also accumulated more than 1,700 U.S. patient start forms by the end of February 2026. Deucrictibant will therefore enter an oral market with an incumbent, not create the category from zero.

Pharvaris will attempt to differentiate through a single-capsule profile, complete symptom resolution, rapid End of Progression and direct B2-receptor blockade. Cross-trial comparisons are unreliable because trial populations, endpoints and statistical methods differ. The real commercial comparison will require label review and real-world physician experience.

Prophylaxis competitors

Competitive update: Chiesi completed the acquisition of KalVista on June 11, 2026. EKTERLY therefore has the backing of a larger rare-disease group. KalVista’s last public Q1 filing reported $39.2M net product revenue for the three months ended March 31, 2026; the earlier $49.1M figure discussed above relates to the 2025 transition period, not a current quarterly run rate.

16 Financial Position, Cash Burn and Dilution

Pharvaris ended June 30, 2026 with €318.3 million in cash and cash equivalents, up from €291.7 million at December 31, 2025: the May offering more than covered the half-year burn. Second-quarter research and development expense was €35.0 million against €29.6 million a year earlier, general and administrative expense €15.8 million against €10.8 million, and the net loss €47.8 million against €45.5 million a year earlier. The loss per share moved the other way, from €0.83 to €0.70, because the share count rose.

Across the first half operating expenses reached €95.1 million and the net loss €87.0 million, but the cash line tells the sharper story: €86.6 million of cash used in operating activities, against €68.5 million in the same period of 2025, a 26% increase. Financing activities brought in €105.8 million and exchange differences a further €7.4 million: together they bridge the €291.7 million of December 2025 to the €318.3 million of June 30. Contractual obligations and commitments at June 30 stood at €118 million, mostly research and development contracts, and management states it has not identified significant going-concern risks.

In May 2026 the company sold 4,455,863 ordinary shares, including the underwriters’ full option on 581,199 shares, at $29.68 each, for gross proceeds of about $132.3 million. The offering closed on May 11 and produced net proceeds of about €105.7 million, or $124.3 million, after roughly €6.7 million of bank fees. Management states that the financing extends the cash runway into 2028.

What the financing accomplished

• Reduced near-term financing pressure before CHAPTER-3.
• Funded continued late-stage development and commercial preparation.
• Improved the company’s ability to negotiate from a position of strength.
• Created runway through the visible 2027 PDUFA cycle.

What the financing did not solve

• Pharvaris remains pre-revenue and cash flow negative.
• Commercial launch, inventory, medical affairs and payer access will raise spending.
• A second major regulatory setback could require additional capital before sustainable revenue.
• Equity issuance increased the share count and diluted existing holders.

Share-count discipline

Note 13 of the June 30 interim accounts explicitly reports 70,204,506 ordinary shares. This filed count takes precedence over dividing rounded euro share capital by €0.12 par value, which produces a two-share rounding difference. The May prospectus’s option and RSU counts are dated December 31, 2025 and are not a current fully diluted count. Later issuance, exercises and vesting must be reconciled separately.

Equity incentives, dilution and finite runway remain relevant after the positive CHAPTER-3 result. Stronger clinical evidence can improve financing options, but it does not rule out further capital raising.

The into-2028 runway is management guidance based on planned spending. €318.3M is the June cash balance, not today’s cash; the €118M commitments are not an immediate lump-sum payment, and should not be subtracted again if already included in a forward spending plan.

17 Valuation Context: What the Market Is Already Paying For

The September 4 Marketstack close is $35.25. Applied to the 70,204,506 SEC shares at June 30, it gives approximately $2.475B basic equity value. Finviz separately reports $2.463B on its own capitalization basis; the measures are not identical. Neither is a fully diluted enterprise value. Euro cash must be converted using an explicitly dated exchange rate before any dollar EV calculation.

That valuation changes the question. Investors are not merely deciding whether deucrictibant works. They are deciding whether the combined on-demand and prophylaxis franchise can become large enough to justify a multi-billion-dollar pre-revenue value after accounting for development risk, launch spending and competition.

A practical sum-of-the-parts framework

18 Ownership, Short Interest and Analyst Coverage

Pharvaris has substantial specialist institutional ownership. Its 2025 annual report identified several holders above the 5% reporting threshold, and third-party ownership aggregators list investors such as General Atlantic, Foresite, venBio, FMR, Bain Capital Life Sciences, Deerfield and Commodore among major historical holders. Ownership data can lag and should be verified through current Schedule 13D/13G and Form 13F filings.

High-quality healthcare ownership can support credibility and liquidity, but concentrated sponsorship can also amplify volatility. Large funds may rebalance around a binary catalyst, lock in gains after positive data or reduce risk before a readout. A strong shareholder list is not a substitute for clinical evidence.

Insider filings verified in the available SEC record

Two Form 4 filings landed after the second-quarter release. On August 18 chief executive Berndt Modig reported the sale of 2,292 shares on August 14 at a weighted average of $34.7669, shares acquired on the vesting of restricted stock units and sold under a Rule 10b5-1 plan, leaving 130,625 held directly alongside the indirect holding through Schoodic Management BV. It is the same size as the July 13 sale of 2,292 shares at $34.9714. On August 13 president Lu Peng reported 109 and 117 shares withheld by the issuer on August 11 and 12 to cover tax on vesting restricted stock units, at $34.84 and $34.42, leaving 65,179 shares. Withholding is not a sale into the market and the Rule 10b5-1 box on that filing is unchecked.

General Atlantic reported 7.6% on August 14. A Schedule 13G/A filed by General Atlantic, L.P. and affiliated entities reports 5,359,727 ordinary shares, 7.6% of the class, held with shared voting and dispositive power, as of June 30, 2026. The event date is the quarter end, so the figure describes the position two months before the filing rather than today.

Short interest

Finviz retrieved September 6 shows 33.05M float shares, short float 5.37%, days to cover 3.46, institutional ownership 47.94% and insider ownership 52.70%. Multiplying float by short percentage implies about 1.775M shares short, an approximate cross-field calculation rather than a separately verified exchange settlement count. Ownership categories overlap; they must not be normalized into a pie that pretends they partition the share register.

Sell-side coverage

The company’s Investor Relations page currently lists coverage from BofA Securities, Cantor, Citizens, Guggenheim, H.C. Wainwright, JonesResearch, KBC Securities, Leerink Partners, Morgan Stanley, Oppenheimer, RBC Capital Markets, Van Lanschot Kempen, Wedbush Securities and Wells Fargo. Analyst opinions belong to the firms and do not represent Pharvaris or Merlintrader.

Retail sentiment · September 6

The retrieved feed centers on the coming data and fund positioning, with sparse relevant posts and repeated cross-ticker messages. Rumored event returns and acquisition speculation are not company guidance. The Merlintrader post in the feed is our own prior publication, not independent confirmation. Canonical scores are not probabilities or percentages of all holders.

8 September 2026 — H.C. Wainwright: $60 target maintained. Dow Jones via IBKR reported on September 8 that H.C. Wainwright maintained its $60 price target. This is a confirmation, not a target increase. The feed attributes the action to Benzinga; the original broker note was not obtained and no new rating or valuation rationale is established by this brief. It is an attributed analyst view, not company guidance or a Merlintrader recommendation. Benzinga — ratings page referenced by the feed

19 Management, Board and Execution Capability

Berndt Modig serves as Chief Executive Officer. Lu Peng, M.D., Ph.D., serves as President and has held senior medical and development responsibilities. Anne Lesage, Ph.D., leads early development and contributes to the company’s bradykinin biology strategy. David Nassif serves as Chief Financial Officer. The broader team includes executives with rare-disease and HAE development experience.

Management has recovered from the prior U.S. clinical holds, completing RAPIDe-3, enrolling CHAPTER-3, submitting the NDA and raising capital before the most important near-term readout. Those achievements demonstrate execution. The next phase is different: building a commercial organization, validating manufacturing, negotiating payer access and managing two potential product launches requires capabilities beyond clinical development.

Governance points to monitor

• Executive compensation and equity-award growth relative to milestones.
• Insider selling or option exercises around major events.
• Board independence and rare-disease commercialization expertise.
• Capital allocation between launch preparation, CREAATE and speculative expansion.
• Whether management communicates full datasets rather than relying on promotional headline metrics.

20 Manufacturing, Supply Chain and Intellectual Property

Pharvaris relies on third-party contract development and manufacturing organizations. Its 2025 annual report described two CDMOs for active pharmaceutical ingredient production, separate partners for the IR capsules and XR tablets, and additional organizations for packaging, labeling and distribution. This is a common biotechnology model, but the company does not control the facilities directly.

The company reported that it had established a scalable synthetic route and that raw materials could be sourced from multiple suppliers. The intended commercial formulations are already being used in the pivotal and filing programs, which reduces but does not eliminate comparability risk.

CMC remains a major regulatory risk

Many late-stage biotechnology applications fail or are delayed for manufacturing rather than efficacy. The FDA will evaluate process validation, stability, impurities, packaging, supplier controls and inspection findings. Because the IR and XR products use different formulations and manufacturing partners, each has its own CMC package even though the active ingredient is shared.

Patent estate

As of December 31, 2025, Pharvaris reported ownership of five U.S. patents and approximately 150 national or regional patents, plus 85 pending applications worldwide. The portfolio included composition-of-matter claims, methods of use and formulation claims. The company stated that relevant patents expire in 2038 or later before possible patent-term extensions or adjustments.

Composition-of-matter protection is the most important layer because it covers the molecule itself. Formulation and method patents can extend or reinforce protection but are often easier to challenge or design around. Orphan exclusivity and regulatory data exclusivity may provide additional protection if approval is obtained.

21 Bull, Mixed and Bear Scenarios

Bull scenario

Constructive scenario after positive topline: the complete XR dataset supports regulatory submissions from H1 2027, IR review proceeds favorably, and manufacturing and payer readiness enable competitive launches if approved.

What would support it: consistent subgroups, rapid onset of prophylactic protection, low discontinuation, strong quality-of-life results and a credible filing timeline for XR.

Mixed scenario

Middle scenario: positive XR efficacy is preserved, but regulatory timing, access or competitive positioning limits adoption. Approval and commercial outcomes remain uncertain despite the met primary endpoint.

What would support it: adequate efficacy with manageable gastrointestinal or other adverse events, a reasonable attack-free rate and a clear patient subgroup with strong benefit.

Bear scenario

Adverse scenario after positive topline: additional safety, manufacturing or regulatory requirements delay development, or reimbursement and competition undermine commercial value. A hypothetical miss of the already-met CHAPTER-3 primary endpoint is no longer the forward scenario.

What would confirm it: inconsistent results, high discontinuation, exposure problems, unexplained subgroup failures or management delaying the full dataset.

Scenario asymmetry

The remaining downside concerns review, durability, safety and commercialization across two HAE programs. The positive CHAPTER-3 result reduces a specific clinical uncertainty without eliminating those risks.

22 Risk Register and Monitoring Checklist

Pre-catalyst checklist

• Confirm that CHAPTER-3 data have not already been released.
• Record the latest market capitalization and fully diluted share count.
• Review any new SEC filing, financing or insider transaction.
• Check competitor news from KalVista, BioCryst, Takeda, Ionis and CSL.
• Verify whether the company has narrowed the Q3 window.
• Separate company claims from independently published or regulator-reviewed evidence.
• Define in advance what attack rate, attack-free percentage and safety profile would qualify as strong, mixed or weak.

23 How to Read the CHAPTER-3 Press Release

Biotechnology press releases are designed to emphasize the strongest interpretation. The result can be reconstructed methodically.

A headline such as “met the primary endpoint” is insufficient. A commercially strong result should show that patients experience few attacks, remain on therapy and avoid rescue treatment. If the release emphasizes only relative reductions, trademarked endpoints or selected subgroups while delaying absolute rates and safety details, caution is appropriate.

24 Merlintrader Bottom Line

Positive RAPIDe-3 and CHAPTER-3 results now support the on-demand and prophylaxis programs respectively. The next step is regulatory and commercial execution: IR review is dated, while XR filings remain planned from H1 2027.

The bull case is powerful: one active ingredient, oral administration in both treatment settings, a validated mechanism, a credible team and sufficient capital to reach the major milestones. The bear case is equally clear: a crowded market, a first-mover oral competitor, single-molecule concentration and a valuation that already assumes meaningful success.

The relevant question after positive topline is whether the full profile can change prescribing behavior in an HAE market already served by effective treatments; the trial was not a head-to-head comparison with those competitors.

25 Follow the next PHVS catalyst updates

CHAPTER-3 data, FDA review developments, competitive HAE launches and financing changes can alter the thesis quickly. Follow Merlintrader for evidence-based updates and new Stock Hub revisions.